Current and emerging options in the treatment of onychomycosis

Seminars in Cutaneous Medicine and Surgery

Volumn 32, Issue , 2013, Pages S9-S12

  Elewski, Boni ^a   Pariser, David ^b   Rich, Phoebe ^c   Scher, Richard K ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Ciclopirox; Efinaconazole; Fluconazole; Fungal infections; Itraconazole; Nail infections; Onychomycosis; Tavaborole; Terbinafines

Indexed keywords

CAMPHOR; CICLOPIROX; CISAPRIDE; EFINACONAZOLE; FLUCONAZOLE; ITRACONAZOLE; LEVACETYLMETHADOL; PIMOZIDE; QUINIDINE; TAVABOROLE; TEA TREE OIL; TERBINAFINE; ANTIFUNGAL AGENT;

ANTIFUNGAL THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; DEBRIDEMENT; DRUG INTERMITTENT THERAPY; FINGERNAIL ONYCHOMYCOSIS; FUNGUS CULTURE; HUMAN; INFECTION PREVENTION; LOW LEVEL LASER THERAPY; MULTIPLE CYCLE TREATMENT; NEODYMIUM YAG LASER; ONYCHOMYCOSIS; PHOTODYNAMIC THERAPY; RECURRENT INFECTION; REINFECTION; TINEA PEDIS; TOENAIL ONYCHOMYCOSIS; PRACTICE GUIDELINE; REVIEW;

ANTIFUNGAL AGENTS; HUMANS; ONYCHOMYCOSIS; PRACTICE GUIDELINES AS TOPIC;

EID: 84891609312     PISSN: 10855629     EISSN: 15580768     Source Type: Journal    
DOI: 10.12788/j.sder.0016     Document Type: Article

References (23)

1. Abdullah L, Abbas O. Common nail changes and disorders in older people: Diagnosis and management. Can Fam Physician. 2011;57:173-181
2. Chang CH, Young-Xu Y, Kurth T, Orav JE, Chan AK. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: A meta-analysis. Am J Med. 2007;120:791-798
3. Scher RK, Breneman D, Rich P, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38 (6, pt 2):S77-S86
4. Sporanox (itraconazole) [package insert]. Raritan, NJ: PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc; 2011
5. Evans EGV, Sigurgeirsson B for the LION Study Group. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. BMJ. 1999;318:1031-1035
6. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet. 2001;357:1766-1767
7. Lamisil (terbinafine) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; 2012
8. Drake LA, Shear NH, Arlette JP, et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol. 1997;37(5, pt1):740-745
9. Tosti A, Piraccini BM, Stinchi C, Colombo MD. Relapses of onychomycosis after successful treatment with systemic antifungals: A three-year follow-up. Dermatology. 1998;197:162-166
10. Penlac (ciclopirox 8%) [package insert]. Bridgewater, NJ: Dermik Laboratories; 2006
11. Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68:600-608
12. Tavaborole (AN2690). Available at: http://www.anacor.com/an2690.php. Accessed March 24, 2013
13. Vural E, Winfield HL, Shingleton AW, Horn TD, Shafirstein G. The effects of laser irradiation on Trichophyton rubrum growth. Lasers Med Sci. 2008;23:349-353
14. Murdan S. Enhancing the nail permeability of topically applied drugs. Expert Opin Drug Deliv. 2008;5:1267-1282
15. Borovoy M, Tracy M. Noninvasive CO2 laser fenestration improves treatment of onychomycosis. Clin Laser Mon. 1992;10:123-124
16. Piraccini BM, Rech G, Tosti A. Photodynamic therapy of onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol. 2008;59(5 suppl):S75-S76
17. Watanabe D, Kawamura C, Masuda Y, Akita Y, Tamada Y, Matsumoto Y. Successful treatment of toenail onychomycosis with photodynamic therapy. Arch Dermatol. 2008;144:19-21
18. Donnelly RF, McCarron PA, Lightowler JM, Woolfson AD. Bioadhesive patchbased delivery of 5-aminolevulinic acid to the nail for photodynamic therapy of onychomycosis. J Control Release. 2005;103:381-392
19. Gilaberte Y, Aspiroz C, Martes MP, Alcalde V, Espinel-Ingroff A, Rezusta A. Treatment of refractory fingernail onychomycosis caused by nondermatophyte molds with methylaminolevulinate photodynamic therapy. J Am Acad Dermatol. 2011;65:669-671
20. Gupta A, Brintnell W. Onychomycosis therapy: Past, present, and future. J Am Acad Dermatol. 2012;66(4 suppl 1):AB120
21. Piraccini BM, Sisti A, Tosti A. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol. 2010;62:411-414
22. Gupta A, Cooper E. Examination of cure and relapse of dermatophyte toenail onychomycosis during long-term follow-up after oral therapy. J Am Acad Dermatol. 2012;66(4 suppl 1):AB119
23. Pariser D, Elewski B, Scher RK, Rich P. Promoting and maintaining or restoring healthy nails: Practical recommendations for clinicians and patients. Semin Cutan Med Surg. 2013;33:19-20